Skip to content

Comparison between Onabotulinum toxin type A injection and Phenol injection in improving post stroke spasticity and walking ability.

Comparative study on improvement in gait between between 6% phenol chemoneurolysis and onabotulinum toxin type A in post stroke spasticity - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077262
Enrollment
72
Registered
2024-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I693- Sequelae of cerebral infarction Health Condition 2: I692- Sequelae of other nontraumatic intracranial hemorrhage

Interventions

Intervention1: Chemoneurolysis with 6% phenol: Chemoneurolysis using 6% phenol in posterior tibial nerve/ branches visualized under USG and/or Nerve stimulator, MAS for spasticity improvement and gai

Sponsors

IPGMER AND SSKM HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically and radiologically diagnosed first ever stroke 2. Age of the patient 20-65 (19) years irrespective of gender. 3. 3 months after onset of stroke 4. Spasticity at resting state of Gastrocnemius, soleus, tibialis posterior muscle as defined by MAS scale of 2/3. 5. Brunnstrom recovery stage III-IV 6. MMSE score = 25 7. Consent from the patient.

Exclusion criteria

Exclusion criteria: 1. Other neurological disorder 2.Sensory impairment 3. Osteoarticular disease 4. Past H/O Botox or Phenol injection. 5. MAS =1 + , Adductor muscle spasticity 6. Local site infection 7.No contracture of lower limb or previous surgery for spasticity contracture. 8. Allergy to botulinum toxin type A or Phenol 9. Abnormal coagulation profile 10.Patients suffering from unstable cardio vascular or serious respiratory diseases 11. Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
Improvement in modified ashworth scale , step length, cadence, gait speed, stance phase, swing phaseTimepoint: Pre procedure, 24 hours, 3 weeks , 12 weeks

Secondary

MeasureTime frame
Improvement in modified ashworth scale , step length, cadence, gait speed, stance phase, swing phaseTimepoint: pre procedure, Day 3, 12 weeks

Countries

India

Contacts

Public ContactRAJESH PRAMANIK

IPGMER AND SSKM

RPRAMANIK2000@YAHOO.COM9874690505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026